omega-3 fatty acids in burn

Evaluation the effect of fish oil supplementation on glucose homeostasis and inflammatory markers in patients with mild burn

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231031059911N1

Enrollment

Registered

2023-11-29

Start date

2024-01-21

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild burn. T20-T32

Interventions

Intervention 1: Intervention group: Fish oil (Karen Company, Iran) at a dose of 3 gram per day through gavage for 3 weeks. Intervention 2: Control group: Corn oil at a dose of 3 gram per day through g

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with mild burns or who with less than 20% of the body surface Patients with a level of consciousness higher than 9

Exclusion criteria

Exclusion criteria: Age less than 18 and more than 65 years Moderate to severe burns or involvement of less than 20% of the body surface Patients who need parenteral nutrition other diseases such as thyroid, cardiovascular, cancer, diabetes, kidney and liver disorders

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: At the The beginning of the study (before the start of the intervention) and 21 days after the start of consumption. Method of measurement: Laboratory.;Fasting insulin. Timepoint: At the The beginning of the study (before the start of the intervention) and 21 days after the start of consumption. Method of measurement: ELISA kit.;C-reactive protein. Timepoint: At the The beginning of the study (before the start of the intervention) and 21 days after the start of consumption. Method of measurement: ELISA kit.;Erythrocyte sedimentation rate. Timepoint: At the The beginning of the study (before the start of the intervention) and 21 days after the start of consumption. Method of measurement: Laboratory.	—

Measure

Time frame

Fasting blood glucose. Timepoint: At the The beginning of the study (before the start of the intervention) and 21 days after the start of consumption. Method of measurement: Laboratory.;Fasting insulin. Timepoint: At the The beginning of the study (before the start of the intervention) and 21 days after the start of consumption. Method of measurement: ELISA kit.;C-reactive protein. Timepoint: At the The beginning of the study (before the start of the intervention) and 21 days after the start of consumption. Method of measurement: ELISA kit.;Erythrocyte sedimentation rate. Timepoint: At the The beginning of the study (before the start of the intervention) and 21 days after the start of consumption. Method of measurement: Laboratory.

—

Secondary

Measure	Time frame
Length of hospital stay. Timepoint: from hospital admission to discarge. Method of measurement: counting the days.;Length of intensive care unit stay. Timepoint: From the beginning of hospitalization to discharge from the intensive care unit. Method of measurement: counting the days.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyedeh Neda Mousavi

Zanjan University of Medical Sciences

neda.mousavi@zums.ac.ir+98 24 3370 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026